查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1754225

口干症（口干症）治疗市场规模、份额、趋势及预测（按类型、药物类型、配销通路和地区），2025 年至 2033 年

Xerostomia (Dry Mouth Disease) Therapeutics Market Size, Share, Trends and Forecast by Type, Drug Type, Distribution Channel, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球口干症（口干症）治疗市场规模达7.6303亿美元。展望未来， IMARC Group估计，到2033年，该市场规模将达到10.0731亿美元，2025年至2033年的复合年增长率为2.98%。北美目前占据市场主导地位，2024年的市场份额将超过36.8%，这得益于其完善的医疗保健系统、对疾病认识的加深，以及老年人口和药物治疗导致的口干症发病率上升。

随着干燥症、糖尿病以及癌症患者的放射治疗等口干症发生率的上升，口干症（口干症）治疗市场不断扩张。随着肺癌和人口老化，对有效治疗的需求显着增长。此外，医疗保健专业人员和患者对口干症的认识也日益加深，促使他们寻求治疗方案。此外，包括促泌剂和唾液替代品在内的改良药物配方，由于这些新配方能够为患者提供更佳的疗效和更舒适的体验，也推动了市场的发展。药物输送系统的技术进步，尤其是对个人化医疗的重视，也促进了市场的成长。

在美国，口干症治疗市场正在成长，因为老化、糖尿病和癌症治疗（尤其是头部和颈部放射治疗）等风险因素的发生率很高。标靶疗法的日益普及以及非处方产品的技术进步，为患者提供了更多治疗选择。例如，根据产业报告显示，威斯康辛大学医学院公共卫生学院的研究人员正与PACT合作进行一项临床试验，探索利用患者自身增强干细胞改善干燥症唾液腺功能的可能性。这种创新方法包括从患者骨髓中提取干细胞，激活它们，然后将其註射到唾液腺中。此外，随着对口干症对健康影响的认识不断加深，预计美国对有效且便捷的治疗方法的需求将稳步增长。

口干症（口干症）治疗市场趋势：

唾液刺激剂配方的进展

口干症治疗市场在唾液刺激剂的配方方面取得了一些最重要的进展。然而，对长期有效治疗的需求正在推动这些变化。大多数传统的唾液替代品只能提供暂时的缓解，迫使研究人员寻求更新或创新的药物传递方法，例如黏膜黏附剂、缓释凝胶和基于奈米颗粒的疗法。各公司也将注意力转向植物衍生化合物或再生医学方法，以刺激而非取代这种天然的唾液分泌能力。针对唾液腺功能的生物製剂（例如生长因子和基因疗法）正在开发中，这些生物製剂可能会带来一些长期益处。这种进展透过改善保湿性和减少重复使用频率，提高了患者的依从性和治疗效果。具有更高生物利用度的处方製剂进一步促进了市场的成长。一篇研究文章指出，超过30%的65岁及以上人群患有口干症，因此对能够提高患者依从性并提供持续缓解的创新解决方案的需求日益增长。因此，业界正从缓解症状的产品转向针对口干病因的治疗介入。这将确保患者获得更好的治疗效果。

处方药疗法的接受度日益高于非处方药

随着医疗专业人员的认知度不断提高，以及患者对全面长期管理的关注，口干症治疗市场正从非处方口干缓解产品转向处方药。人工唾液喷雾剂、含片或漱口水等非处方产品仅能缓解症状，却未能解决口干的根本原因。另一方面，处方药，如毛果芸香碱和西维美林，毒蕈碱受体激动剂，能够刺激唾液腺功能，产生持久疗效。此外，一些有前景的临床开发候选药物能够促进唾液分泌和腺体再生，这使得处方治疗成为更可行的选择。医疗保健提供者越来越多地向因干燥综合症、放射治疗或多种药物引起的口干而继发慢性口干症的患者推荐处方治疗。随着製药公司持续投资开发疗效和安全性更高的标靶治疗药物，这种转变预计将推动市场成长。研究表明，高达73.4%接受化疗的患者报告出现口干症，而接受头颈癌放射治疗的患者中，口干症的盛行率则高达90%。这一趋势推动了针对潜在病理的处方治疗的普及。

慢性疾病和药物导致口干症盛行率上升

口干症发生率上升的主要原因是慢性疾病的增加以及药物副作用。糖尿病、干燥症和其他自体免疫疾病等疾病会直接影响唾液腺，导致口干症症状持续很长时间。同样，透过放射线治疗和化学治疗进行的癌症治疗通常会损害唾液腺，导致口干症成为癌症患者的常见副作用。研究表明，口干症影响着13-17%的一般人群，由于多种药物合併使用，老年人的盛行率甚至高达30-40%。抗高血压药、抗忧郁药和鸦片类药物等药物的广泛使用进一步加剧了口干症的发生率，已知有超过400种常用处方药会导致口干副作用。随着全球老化和慢性病负担的不断加重，对有效治疗口干症药物的需求将会增加。因此，製药公司正在研发能够缓解口干症状并解决其根本原因的药物。因此，患者数量的成长代表着口干症治疗市场创新和成长的重要领域。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

  • 概述
  • 主要行业趋势

第五章：全球口干症（口干症）治疗市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场细分：依类型

  • 人工唾液/唾液替代品
  • 唾液刺激剂

第七章：市场区隔：依药物类型

  • 场外交易
  • 处方

第八章：市场区隔：按配销通路

  • 医院药房
  • 零售药局
  • 网路药局

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场区隔：依国家

第十章：SWOT分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第十三章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • 3M Company
    • Biotene (GSK plc)
    • Parnell Pharmaceuticals Inc.
    • Quest Products LLC
    • Saliwell Ltd
    • Sun Pharmaceutical Industries Limited
    • West-Ward Pharmaceutical (Hikma Pharmaceuticals plc)
Product Code: SR112025A6439

The global xerostomia (dry mouth disease) therapeutics market size was valued at USD 763.03 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 1,007.31 Million by 2033, exhibiting a CAGR of 2.98% from 2025-2033. North America currently dominates the market, holding a market share of over 36.8% in 2024, attributed to a well-established healthcare system, increased disease understanding, and growing incidence of dry mouth due to the elderly population and medications.

The xerostomia (dry mouth disease) therapeutics market expands due to rising incidence of dry mouth conditions, involving Sjogren's syndrome, diabetes, and radiation therapy for cancer patients. The effective treatment demand is witnessing a notable increase with lung cancer and an aging population. Additionally, healthcare professionals alongside patients are increasingly aware of dry mouth disease which drives their pursuit of therapeutic solutions. Moreover, improved drug formulations, including secretagogues and saliva substitutes, profilerating the market forward as these new formulations provide better effectiveness and comfort to patients. Technological advances in drug delivery systems with emphasis on personalized medicine also contribute to the market's growth.

In the United States, the xerostomia therapeutics market is growing with a high incidence of risk factors like aging, diabetes, and cancer therapy, especially head and neck radiation. The increasing use of targeted therapies and technological advancements in over-the-counter products are offering increased treatment choices for patients. For instance, as per industry reports, researchers from University of Wisconsin School of Medicine Public Health, in partnership with PACT, is performing a clinical trial to explore the potential of using a patient's own enhanced stem cells to improve salivary gland function in Sjogren's disease. This innovative approach involves extracting stem cells from the patient's bone marrow, activating them, and injecting them into the salivary glands. Furthermore, as the understanding of xerostomia's impact on health continues to evolve, demand for effective and accessible treatments in the U.S. is expected to rise steadily.

Xerostomia (Dry Mouth Disease) Therapeutics Market Trends:

Advancements in Salivary Stimulant Formulations

The xerostomia therapeutics market has some of the most significant advancements in the formulation of salivary stimulants. The demand for prolonged and effective treatment is, however, driving these changes. Most of the classical saliva substitutes provide only temporary relief, forcing researchers to seek newer or innovative drug delivery methods like mucoadhesive formulations, sustained-release gels, and nanoparticle-based therapies. Companies have also turned their attention to plant-derived compounds or regenerative medicine approaches to stimulate rather than replace this natural saliva production capability. Biologics are being developed targeting salivary gland function, like growth factors and gene therapy, that might offer some long-term benefits. This development improves patient compliance and the efficacy of the treatment through improved moisture retention and decreased frequency of reapplication. Prescription-based formulations with enhanced bioavailability further add to the market's growth. With over 30% of individuals aged 65 and older experiencing dry mouth, there is a growing need for innovative solutions that improve patient compliance and offer sustained relief, a research article stated. As a consequence, the industry is moving away from symptomatic relief products towards therapeutic interventions targeting the cause of dry mouth. This will ensure better patient outcomes.

Growing Adoption of Prescription Therapies Over OTC Products

The market of xerostomia therapeutics is moving away from OTC dry mouth relief products to more prescription-based drugs based on the increasing awareness within the healthcare professional community and the patients' concern for complete long-term management. While OTC products such as artificial saliva sprays, lozenges, or mouth rinses provide mere symptom relief, it does not take into account the root causes of the dryness. On the other hand, prescription medications such as pilocarpine and cevimeline, muscarinic receptor agonists stimulate salivary gland function to produce long-lasting effects. In addition, promising drug candidates for clinical development involve enhancement of saliva flow and glandular regeneration that positions prescription treatments as a more viable option. The healthcare provider has increasingly become recommending prescription treatments to patients who suffer from chronic xerostomia secondary to Sjogren's syndrome, radiation therapy, or polypharmacy-induced dryness. This shift is expected to fuel market growth as pharmaceutical companies continue investing in the development of targeted treatments with improved efficacy and safety profiles. Studies suggest that up to 73.4% of patients undergoing chemotherapy report experiencing xerostomia, with the prevalence rising to 90% among those receiving radiation therapy for head and neck cancers. This trend is driving the adoption of prescription-based treatments targeting the underlying pathology.

Rising Prevalence of Xerostomia Due to Chronic Diseases and Medications

The principal reason for the rising rate of xerostomia cases is the increased number of chronic diseases and side effects from medication. Diseases like diabetes, Sjogren's syndrome, and other autoimmune diseases have a direct impact on salivary glands, causing symptoms of xerostomia to be felt for long durations. Similarly, cancer treatments through radiation therapy and chemotherapy often damage salivary glands, thereby resulting in xerostomia as a common side effect in cancer patients. Studies indicate that xerostomia affects 13-17% of the general population, with prevalence rates rising to 30-40% among the elderly due to polypharmacy. The widespread use of medications such as antihypertensives, antidepressants, and opioids further contributes to the rising number of cases, with over 400 commonly prescribed drugs known to cause dry mouth as a side effect. Demand for effective remedies against xerostomia will increase among the aging globe and the constantly growing burden of chronic diseases. As such, pharmaceutical companies are coming forward with the drugs that can offer symptomatic relief and address the underlying cause of dry mouth. The rising number of patients, thus, represents an important area for innovation and growth in the xerostomia therapeutics market.

Xerostomia (Dry Mouth Disease) Therapeutics Industry Segmentation:

Analysis by Type:

  • Artificial Saliva/Saliva Substitutes
  • Salivary Stimulants

Artificial saliva/saliva substitutes lead the market with around 65.7% of market share in 2024. due These products provide moisture, lubrication, and relief from dry mouth symptoms, improving patients' comfort and quality of life. Available in various forms, such as sprays, gels, and lozenges, artificial saliva products help alleviate discomfort caused by conditions like Sjogren's syndrome or medication-induced xerostomia. Their widespread use in both clinical settings and over-the-counter offerings, along with ongoing advancements in formulation, continues to drive demand, positioning them as a key treatment option for dry mouth management.

Analysis by Drug Type:

  • OTC
  • Prescription

OTC leads the market in 2024, driven by consumer preference for easily accessible, non-prescription solutions. OTC treatments, including mouthwashes, lozenges, gels, and sprays, offer immediate relief from dry mouth symptoms and are widely available in pharmacies and online. The growing trend of self-management and the increasing awareness of xerostomia contribute to the popularity of OTC products. Additionally, their affordability and convenience make them a preferred choice for patients seeking to manage mild to moderate cases of dry mouth without the need for a healthcare provider's prescription.

Analysis by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Retail pharmacy leads the market with around 38.5% of market share in 2024, due to their wide accessibility and convenience for consumers. Patients can easily obtain over-the-counter (OTC) products such as mouthwashes, lozenges, and gels, which are commonly used to manage dry mouth symptoms. The growing preference for self-management of xerostomia, along with the increasing number of retail pharmacy chains globally, has bolstered this segment. Retail pharmacies also benefit from strong relationships with pharmaceutical companies, enabling them to stock a diverse range of therapeutics. Additionally, their ability to provide personalized advice and quick access further drives their dominance in the market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, North America accounted for the largest market share of over 36.8%, driven by a high prevalence of dry mouth conditions, advanced healthcare infrastructure, and significant investments in research and development. The region's large aging population, particularly in the U.S., contributes to the rising incidence of xerostomia, often linked with medication use, autoimmune diseases, and radiation therapy for cancer treatment. For instance, industry reports state that the U.S. population aged 65 plus is projected to grow from 58 million in 2022 to 82 million by 2050, increasing from 17% to 23% of the total population. Additionally, the presence of key pharmaceutical companies, a robust pipeline of therapeutic products, and favorable reimbursement policies further support market growth. North America's demand for innovative treatments and patient-centered care strategies ensures its leadership in this market.

Key Regional Takeaways:

United States Xerostomia (Dry Mouth Disease) Therapeutics Market Analysis

In 2024, United States accounted for 88.6% of the market share in North America. The U.S. Xerostomia (Dry Mouth Disease) therapeutics market is growing due to the increasing number of chronic patients, such as diabetes and Sjogren's syndrome, among others. According to CDC, in 2023, about 37.3 million Americans had diagnosed diabetes, accounting for a big portion of individuals with dry mouth. Moreover, the growing need for prescription dry mouth treatments by cancer patients after radiation therapy enhances the demand. New saliva substitutes, oral sprays, and regenerative therapies are creating advanced treatment avenues. Developed healthcare system in the United States ensures increased accessibility to xerostomia treatments for patients. Major pharmaceutical giants, GlaxoSmithKline and Colgate-Palmolive, are looking for expansion in their portfolios of oral health care. Government-aided health care, Medicare, and Medicaid continue to make treatments affordable for patients, and increasing awareness programs also facilitate timely diagnosis and adherence to treatments. The integration of AI in dental healthcare is also improving patient outcomes, positioning the U.S. as a key market for xerostomia therapeutics.

Europe Xerostomia (Dry Mouth Disease) Therapeutics Market Analysis

The European Xerostomia therapeutics market is experiencing growth due to the aging population and increasing diabetes and autoimmune cases. It is estimated by the World Health Organization (WHO) that about 74 million adults and 300,000 children and adolescents in Europe are suffering from diabetes, the greatest risk factor for xerostomia. In addition, an increase in the number of cancer patients treated using radiation therapy causes a boosted demand for saliva substitutes and prescription treatments. Germany and France lead the market in terms of adoption since their healthcare systems are well established. Unilever and Reckitt companies are taking a challenge to apply innovative oral hydration solutions and prescription medicines. European Union rules promoting access to advanced patient therapies support market expansion, as increased research and development result in novel treatment solutions, positioning Europe as a central market for xerostomia therapeutics.

Asia Pacific Xerostomia (Dry Mouth Disease) Therapeutics Market Analysis

Asia Pacific is experiencing a huge growth in the Xerostomia therapeutics market due to the increasing diabetic population and the increasing awareness of oral health. The International Diabetes Federation (IDF) states that by 2023, China had around 140 million people living with diabetes, significantly contributing to the prevalence of dry mouth. The elderly population in Japan, at about 29% of the total population, further fuels the demand for xerostomia treatments. The potential for the market increases in addition to government healthcare services in the form of various schemes, such as Ayushman Bharat by India, which encourages oral health awareness. Herbal and natural saliva substitutes are emerging nowadays, especially in countries like China and India. Pharmaceutical companies like Sun Pharma and Takeda are increasing their market presence both domestically and internationally. The increasing use of digital healthcare platforms is enhancing access to treatment, making Asia Pacific a key region for market growth.

Latin America Xerostomia (Dry Mouth Disease) Therapeutics Market Analysis

The Latin American Xerostomia therapeutics market is growing because of increased investments in healthcare and the rising prevalence of chronic diseases. According to an industry report, Brazil's healthcare spending has reached USD 161 billion in 2023, with a significant share spent on oral health care, as per reports. Increasing cases of xerostomia caused by diabetes and cancer treatments are pushing the demand for therapeutic solutions. Brazil and Mexico have the largest market share in that region, therefore, are shifting their focus toward increasing prescription-only dry mouth therapies. According to an industry report, more than 1.7 million aesthetic and dental operations were conducted within Mexico in the year 2023, contributing to the augmented demand for oral hydration solutions. Multinational companies are coming together with regional firms to create advanced saliva substitutes and prescription-only medications. The market growth in the region is likely to be sustained by government-backed healthcare programs and rising private investments in oral health care.

Middle East and Africa Xerostomia (Dry Mouth Disease) Therapeutics Market Analysis

Middle East and Africa Xerostomia therapeutics market is also witnessing growth in this region as there is growing healthcare investment coupled with a higher incidence of chronic diseases such as diabetes. As per the UAE government data, the federal healthcare budget for 2022 was USD 1.16 billion. It allocated most of the healthcare budget to oral healthcare services. Diabetes is quite prevalent in this region, particularly in the gulf countries. The demand for prescription medication, such as pilocarpine, in Saudi Arabia is on the rise due to an incidence rate of over 18% for diabetes. In South Africa, increasing production by pharmaceutical companies contributes to increased oral hydration solution availability. Dental and oral healthcare awareness is further bolstering the market within the region. Investments in health infrastructure, along with collaborations between local and international pharmaceutical companies, are likely to boost the growth of advanced treatments for xerostomia.

Competitive Landscape:

The competition among the established pharmaceutical firms and emerging biotechnology companies drives the market for xerostomia (dry mouth disease) therapeutics. The key players are focused on the development and commercialization of some products, including saliva substitutes, secretagogues, and therapies focusing on the underlying causes of xerostomia. Companies are putting in substantial investments to create new drug formulations and sophisticated delivery systems to fill unmet needs in patient care. Besides, firms often take on strategic partnerships and acquisitions to base their portfolios of products and enhance market reach. Competition is further influenced by important aspects, such as regulatory approvals, pricing strategies, and clinical effectiveness. For instance, in December 2024, MeiraGTx Holdings announced that they received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for their product AAV2-hAQP1 for the treatment of Grade 2/3 radiation-induced xerostomia. This designation highlights the therapy's potential to address unmet needs, expedite development, and enhance patient outcomes for those affected by radiation-induced dry mouth.

The report provides a comprehensive analysis of the competitive landscape in the xerostomia (dry mouth disease) therapeutics market with detailed profiles of all major companies, including:

  • 3M Company
  • Biotene (GSK plc)
  • Parnell Pharmaceuticals Inc.
  • Quest Products LLC
  • Saliwell Ltd
  • Sun Pharmaceutical Industries Limited
  • West-Ward Pharmaceutical (Hikma Pharmaceuticals plc)

Key Questions Answered in This Report

  • 1.How big is the xerostomia (dry mouth disease) therapeutics market?
  • 2.What is the future outlook of xerostomia (dry mouth disease) therapeutics market?
  • 3.What are the key factors driving the xerostomia (dry mouth disease) therapeutics market?
  • 4.Which region accounts for the largest xerostomia (dry mouth disease) therapeutics market share?
  • 5.Which are the leading companies in the global xerostomia (dry mouth disease) therapeutics market?q

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Xerostomia (Dry Mouth Disease) Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Artificial Saliva/Saliva Substitutes
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Salivary Stimulants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 OTC
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Prescription
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 3M Company
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Biotene (GSK plc)
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Parnell Pharmaceuticals Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Quest Products LLC
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Saliwell Ltd
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Sun Pharmaceutical Industries Limited
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 West-Ward Pharmaceutical (Hikma Pharmaceuticals plc)
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio

List of Figures

  • Figure 1: Global: Xerostomia Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Global: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 4: Global: Xerostomia Therapeutics Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Xerostomia Therapeutics Market: Breakup by Drug Type (in %), 2024
  • Figure 6: Global: Xerostomia Therapeutics Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Xerostomia Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Xerostomia Therapeutics (Artificial Saliva/Saliva Substitutes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Xerostomia Therapeutics (Artificial Saliva/Saliva Substitutes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Xerostomia Therapeutics (Salivary Stimulants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Xerostomia Therapeutics (Salivary Stimulants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Xerostomia Therapeutics (OTC) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Xerostomia Therapeutics (OTC) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Xerostomia Therapeutics (Prescription) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Xerostomia Therapeutics (Prescription) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Xerostomia Therapeutics (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Xerostomia Therapeutics (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Xerostomia Therapeutics (Retail Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Xerostomia Therapeutics (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Xerostomia Therapeutics (Online Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Xerostomia Therapeutics (Online Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: North America: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: North America: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: United States: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: United States: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Canada: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Canada: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Asia-Pacific: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Asia-Pacific: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: China: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: China: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Japan: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Japan: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: India: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: India: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: South Korea: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: South Korea: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Australia: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Australia: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Indonesia: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Indonesia: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Others: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Others: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Europe: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Europe: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Germany: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Germany: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: France: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: France: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: United Kingdom: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: United Kingdom: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Italy: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Italy: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Spain: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Spain: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Russia: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Russia: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Others: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Others: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Latin America: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Latin America: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Brazil: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Brazil: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Mexico: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Mexico: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Others: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Others: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Middle East and Africa: Xerostomia Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Middle East and Africa: Xerostomia Therapeutics Market: Breakup by Country (in %), 2024
  • Figure 70: Middle East and Africa: Xerostomia Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Global: Xerostomia Therapeutics Industry: SWOT Analysis
  • Figure 72: Global: Xerostomia Therapeutics Industry: Value Chain Analysis
  • Figure 73: Global: Xerostomia Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Xerostomia Therapeutics Market: Key Industry Highlights 2024 and 2033
  • Table 2: Global: Xerostomia Therapeutics Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Xerostomia Therapeutics Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 4: Global: Xerostomia Therapeutics Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Xerostomia Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Xerostomia Therapeutics Market: Competitive Structure
  • Table 7: Global: Xerostomia Therapeutics Market: Key Players